NCCN 2015 Congress Series™: Genitourinary (GU) Cancers

Orange, CT US
November 11, 2015

This educational initiative addresses healthcare professionals’ need to be educated on practice-changing developments in the management of advanced genitourinary cancers that have taken center stage in recent years. The expansion of treatment options has improved patient care but has presented numerous clinical challenges.  For example, despite significant improvements in responses and survival with the use of TKIs and mTOR inhibitors as first-line therapy in patients with RCC, progression is universal in these patients. This underscores the need to understand optimal second-line therapy, optimal sequence of therapies, and novel treatment approaches such as immunotherapeutics that are currently in various phases of clinical development.

Metastatic prostate cancer has seen rapid expansion of therapeutic options, and, therefore, clinicians managing these patients are challenged to acquire, comprehend, and integrate the latest clinical evidence and recommendations. Additionally, prostate cancer and its treatments are associated with a diverse array of possible symptoms that can have a large negative impact on men’s quality of life both during and after treatment. Clinicians need to be updated on management strategies for the most common and troubling symptoms, including important novel treatments for patients with bone metastases that can improve bone health and prolong survival.

Although the standard of care for the treatment of advanced bladder cancer has remained mostly unchanged over the last 30 years, clinical trial data continue to provide insight into potential new therapies. The use of bladder-preserving strategies has improved quality of life, and newer agents that include molecularly targeted therapies and immunotherapies may further improve patient outcomes.

Target Audience

This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, urologists, and other healthcare professionals who manage patients with GU cancers.

Learning Objectives

Following this activity, participants should be able to:

Renal Cell Carcinoma (RCC)

  • Explain the molecular biology of renal cell carcinoma
  • Categorize the risks and benefits of the current therapeutic options available for patients with newly diagnosed advanced renal cell carcinoma
  • Select optimal subsequent lines of treatment to improve outcomes of patients with advanced RCC
  • Discuss the scientific rationale used in developing current and emerging therapeutics for advanced RCC
  • Recognize the toxicities of current targeted therapies used in the treatment of advanced RCC and outline the strategies used to effectively manage these toxicities
  • Employ appropriate patient education regarding toxicities associated with individual treatment plans

Castration-Resistant Prostate Cancer (CRPC)

  • List novel therapies for metastatic prostate cancer that received approval in recent years
  • Discuss patient selection criteria for the various therapeutic options used in the treatment of metastatic prostate cancer
  • Identify optimal sequences and combinations of hormone therapy, immunotherapy, chemotherapy, and other agents for treating metastatic prostate cancer
  • Describe some of the most common symptoms associated with prostate cancer and its treatment
  • Employ treatment strategies that can help prevent or delay bone symptoms associated with androgen deprivation therapy and/or bone metastases
  • Outline strategies for managing other symptoms associated with prostate cancer and its treatment

Advanced Bladder Cancer

  • Summarize the evaluation of patients with recurrent/persistent disease and factors that determine the management and therapeutic aims for these patients
  • Discuss the types of therapies available in clinical trials for patients with advanced bladder cancer
Additional information

Supported by an independent educational grant from Astellas and Medivation, Inc.

Supported by educational grants from:

  • Bristol-Myers Squibb
  • Novartis Pharmaceuticals Corporation
  • Prometheus Laboratories Inc.
Course summary
Available credit: 
  • 3.00 Participation
  • 3.48 Nurse
  • 3.00 Pharmacist
  • 3.00 Physician
Course opens: 
Course expires: 
Event starts: 
11/11/2015 - 8:00am EST
Event ends: 
11/11/2015 - 12:30pm EST
Yale West Campus Conference Center
100 West Campus Drive
Grace Murray Hopper Auditorium
Orange, CT 06477
United States

This activity is approved for AMA PRA Category 1 Credit(s)™ for physicians and is also accredited for nurses and pharmacists. View complete accreditation details

Available Credit

  • 3.00 Participation
  • 3.48 Nurse
  • 3.00 Pharmacist
  • 3.00 Physician


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing